NEW YORK (GenomeWeb) – PerkinElmer reported after the close of the market on Thursday that its first quarter revenues rose 3 percent year over year, thanks largely to an 8 percent revenue growth in its diagnostics business.

For the three months ended April 2, the company reported revenues of $514.1 million, up from $498.0 million a year earlier, and beating the average Wall Street analyst estimate of $506.8 million. Organic revenues increased 4 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.